TOLERABILITY AND EFFICACY OF ISRADIPINE IN CHINESE HYPERTENSIVES IN GENERAL-PRACTICE
Publication in refereed journal


Full Text

Times Cited
Web of Science0WOS source URL (as at 10/08/2020) Click here for the latest count

Other information
AbstractA multicenter open study of isradipine in 449 Asian patients, mainly of Chinese extraction, with mild to moderate hypertension was conducted in general practice in Hong Kong and Singapore. The initial dosage was 2.5 mg BID and this was doubled or halved after four weeks, if necessary. Side effects were reported in 18.7% of patients and caused withdrawal from the study in 2.4%. Another 15% of patients were lost to follow-up. The incidence and pattern of side effects were similar to those reported in other studies with isradipine or with placebo. The overall reductions in blood pressure over six weeks in evaluable patients were 23/14 mmHg supine and 21/14 mmHg standing with normalization and responder rates of 82% and 74%, respectively. Patients responding less well showed further improvement with a dosage increase from 2.5 mg BID to 5 mg BID, whereas those showing the greatest response maintained most of the effect when dosage was reduced to 1.25 mg BID.
All Author(s) ListTOMLINSON B, CRITCHLEY JAJ, WOO J, TEOH R
Journal nameCurrent Therapeutic Research
Year1992
Month3
Day1
Volume Number51
Issue Number3
PublisherEXCERPTA MEDICA INC
Pages448 - 455
ISSN0011-393X
LanguagesEnglish-United Kingdom
Web of Science Subject CategoriesMedicine, Research & Experimental; MEDICINE, RESEARCH & EXPERIMENTAL; Pharmacology & Pharmacy; PHARMACOLOGY & PHARMACY; Research & Experimental Medicine

Last updated on 2020-11-08 at 01:59